Ernexa Advances ERNA-101 Toward First-in-Human Study As IND Filing Nears

Ernexa Therapeutics (ERNA) said it is preparing to transition into a clinical-stage biotechnology company as its lead oncology candidate, ERNA-101, moves toward a planned IND submission in the third quarter of 2026.